vTv Therapeutics, Inc.:
June 2019 positive data for TTP399 as an add-on therapy to insulin therapy in a 12 week phase 1/2 trial in patients with T1D. Results from the second part of the Ph2 study expected Q1 2020. Recently announced the first patient has been screened for the Ph2 proof of concept study evaluating the safety and efficacy of azeliragon in patients with mild Alzheimer's disease and Type 2 Diabetes. Data-in hand from two Ph. 2 Diabetes (T2) trials: 1. Glucokinase Activator (TTP399); 2. Oral GLP-1r (TTP273). Recently licensed rights to its PDE4 program to Newsoara Biopharma to further its development in China and other Pacific Rim companies as a potential therapeutic for COPD.
Phase III, Phase l or ll
Central Nervous System, Diabetes
4170 Mendenhall Oaks Parkway
High Point, NC 27265
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by